- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02366104
Brasília Study on Healthy Aging (BSHA)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Non-institutionalized outpatients under preventive care were voluntarily enrolled into the study. Participants were aged of 80 years or over, have never manifested myocardial infarction, stroke or peripheral arterial disease. Enrolled participants underwent a detailed clinical examination, including assessment of anthropometric measures, quality of life by the WHOQOL-BREF, psychological test by Geriatric Depression Scale (GDS) and cognitive function by the mini-mental state examination (MMSE). After 12h of overnight fasting, the study participants underwent to blood sampling collection for biochemical analysis and freezing of plasma, serum and DNA. Immediately after blood collection, participants underwent to cardiovascular ultrasound evaluations and computed tomography (CT) scans during the week following the initial assessment. After baseline measurements, all participants were referred to the study as outpatient clinic for prospective medical follow-up evaluations.
Anthropometric measures: body weight, height, waist circumference and skinfold thickness (triceps, biceps, suprailiac and subscapular) were measured. Body mass index (BMI) was calculated. Skinfold thickness was the mean of triplicate measurements at the right side, using a skinfold caliper (WCS Plus®, Cardiomed, Curitiba, Brazil).
Biochemical analysis: After collection, EDTA blood was centrifuged at 5 ◦ C, 4500 rpm for 15min to separate plasma and carrying out the following measurements: glucose (Glucose GOD-PAP, Roche Diagnostics, Mannheim, USA), total cholesterol (CHOD-PAP, Roche Diagnostics, Mannheim, USA), triglycerides (GPO-PAP, Roche Diagnostics, Mannheim, USA), HDL-C (HDL cholesterol without pretreatment, Roche Diagnostics, Mannheim, USA), C-reactive protein (highly sensitive, CardioPhase, Dade Behring, Marburg, USA), urea and creatinine (GLDH, Hitachi, Tokyo, Japan), fibrinogen (Sysmex CA 1500, Siemens, Munich, Germany), interleukin (IL) 10 and tumor necrosis factor type alpha (TNF-alpha) (eBioscience, San Diego, CA, USA). Parathyroid hormone (PTH) and calcitonin (Immulite 2000, Siemens, Los Angeles, CA, USA), bone fraction of alkaline phosphatase (Hitachi Autoanalyzer, Tokyo Japan), calcium (Hitachi Autoanalyzer, Tokyo, Japan), apoA and apoB (Behring Nephelometer BNII, Dade Behring, Marburg, Germany) were also measured.
Carotid ultrasound: The evaluation of intima-media thickness (IMT) and presence of carotid plaques were assessed using high-resolution B-mode ultrasound (Philips, model IE 33, 3-9 MHz linear transducer, Philips Medical Systems, Andover, MA, USA) according to the protocols of the American Association of Echocardiography. Bilateral measurements were made at the posterior wall of the bulb of the common carotid artery and at the internal carotid artery through a program of automatic edge detection (QLAB version 6.0 software). Carotid plaque was defined as the presence of focal thickening of at least 50% higher than surrounding areas or as focal region with IMT > 1.5 mm and distinct adjacent edges.
Cardiac computed tomography: Computed tomography was performed in a 64-slice scanner (Aquillion 64, Toshiba, Ottawara, Japan). Axial slices of 3 mm thickness with 3 mm table-feed were acquired at 70% of R-R interval with prospective ECG triggering. Coronary artery calcification was defined as a minimum of 3 contiguous pixels with a peak Hounsfield unit density > 130. Coronary artery calcifications were scored by a certified radiologist. The Agatston score was used to express the value of CAC.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
DF
-
Brasília, DF, Brasil
- Biocárdios - Instituto de Cardiologia
-
-
SP
-
Campinas, SP, Brasil, 13083-887
- University of Campinas
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Aged of 80 years or over
Exclusion Criteria:
- Manifested atherosclerotic disease (MI, stroke or peripheral arterial disease) according to medical evaluation, electrocardiogram and echocardiogram
- Functional dependence or institutionalization
- Cognitive impairment assessed by mini-mental state examination (< 13 points)
- Use of any anti-inflammatory in the last 30 days
- Current or previous diagnosis of neoplastic or immune inflammatory disease
- Chronic obstructive pulmonary disease
- Glomerular filtration rate < 25 mL/min/1.73 m2
- Hepatic disease (ALT or AST ≥ 1.5 upper reference limit)
- Chronic infectious disease (≥ 3 months)
- Left ventricular ejection fraction < 50% on echocardiography
- Manifested neoplasia at admission or until the first year after enrollment
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Grupo
- Perspectivas temporales: Futuro
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Mortalidad por cualquier causa
Periodo de tiempo: 1 año
|
1 año
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Major cardiovascular events
Periodo de tiempo: 2 years
|
Sudden cardiac death (unrelated to trauma, unexpected, and occurring in less than six hours after onset of symptoms), fatal MI (any death preceded by MI) or non-fatal MI.
|
2 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Andrei C Sposito, Ph.D., University of Campinas
Publicaciones y enlaces útiles
Publicaciones Generales
- Freitas WM, Quaglia LA, Santos SN, de Paula RC, Santos RD, Blaha M, Rivera JJ, Cury R, Blumenthal R, Nadruz-Junior W, Agatston A, Figueiredo VN, Nasir K, Sposito AC; Brazilian Study on Healthy Aging. Low HDL cholesterol but not high LDL cholesterol is independently associated with subclinical coronary atherosclerosis in healthy octogenarians. Aging Clin Exp Res. 2015 Feb;27(1):61-7. doi: 10.1007/s40520-014-0249-4. Epub 2014 Jun 7.
- Henriques AD, Tonet-Furioso AC, Machado-Silva W, Freitas WM, Quaglia LA, Santos SN, Cordova C, Sposito AC, Nobrega OT; Brazilian Study on Healthy Aging Group. Apoliprotein E genotype is associated with apoliprotein B plasma levels but not with coronary calcium score in very elderly individuals in primary care setting. Gene. 2014 Apr 15;539(2):275-8. doi: 10.1016/j.gene.2014.01.077. Epub 2014 Feb 12.
- Souza VC, Freitas WM, Quaglia LA, Santos SN, Cordova C, Sposito AC, Nobrega OT. Osteopontin in bone mineral density of very old Brazilians. J Bone Miner Metab. 2013 Jul;31(4):449-54. doi: 10.1007/s00774-013-0425-1. Epub 2013 Mar 21.
- Costa AP, de Paula RC, Carvalho GF, Araujo JP, Andrade JM, de Almeida OL, de Faria EC, Freitas WM, Coelho OR, Ramires JA, Quinaglia e Silva JC, Sposito AC; Brasilia Heart Study Group. High sodium intake adversely affects oxidative-inflammatory response, cardiac remodelling and mortality after myocardial infarction. Atherosclerosis. 2012 May;222(1):284-91. doi: 10.1016/j.atherosclerosis.2012.02.037. Epub 2012 Mar 3.
- Freitas WM, Quaglia LA, Santos SN, Soares AA, Japiassu AV, Boaventura V, dos Santos Barros E, Cordova C, Nobrega OT, Sposito AC. Association of systemic inflammatory activity with coronary and carotid atherosclerosis in the very elderly. Atherosclerosis. 2011 May;216(1):212-6. doi: 10.1016/j.atherosclerosis.2011.01.040. Epub 2011 Feb 2.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- Gerus
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .